LGALS3 and aortic stenosis: Recent studies support the use of this emerging biological marker for the prediction of survival in asymptomatic AS cohorts due to its role in remodeling and the development of congestive heart failure (CHF); however, to our knowledge, no specific studies have been carried out assessing the efficacy of Galectin-3 in the elderly population [12,13,14].